NDA 213312 · Aadi
Fyarro
Sirolimus · Intravenous · mTOR Inhibitor Immunosuppressant; Kinase Inhibitor
Breakthrough therapyPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Sep 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Nov 22, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,853
224 Phase 3, 143 recruiting
FAERS reports
13,519
11,687 serious, 2,180 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 9, 2026.
FYARRO ® is indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). ( 1 )
Mechanism: Sirolimus in FYARRO is an inhibitor of mechanistic target of rapamycin kinase (mTOR, previously known as mammalian target of rapamycin). mTOR, a serine threonine kinase, is downstream of the PI3K/AKT pathway, controls key cellular processes such as cell survival, growth, and proliferation, and is commonly dysregulated in several human cancers. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus-FKBP-12 complex binds to and inhibits activation of the mechanistic target of rapamycin complex 1 (mTORC1)....
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 22, 2021 Original approval · Type 5 - New Formulation or New Manufacturer · priority review Breakthrough therapyOrphanLabelLetterReview
1 products under this application
- FYARRO · SIROLIMUS 100MG/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sirolimus" as an intervention, any sponsor and status, largest first.
- The Dual Antiplatelet Therapy Study (DAPT Study)Pivotal-lookingCompleted
Baim Institute for Clinical ResearchAcademic, hospital or other
NCT00977938 · 25,682 participants · Start Oct 2009 · Primary completion Jun 2014
Drug: Placebo & Aspirin; Clopidogrel & Aspirin, Prasugrel & Aspirin · For: Coronary Artery Disease
Sites: Fairhope, Alabama; Gilbert, Arizona; Phoenix, Arizona · 256 sites in all
- Effect of Different Anti-platelet Strategies on the Long-term Outcome After Sirolimus Drug-eluting Stent ImplantationPivotal-lookingStatus unknown
Sir Run Run Shaw HospitalAcademic, hospital or other
NCT01233167 · 5,232 participants (planned) · Start Aug 2011 · Primary completion Dec 2012
Drug: clopidogrel; placebo and 1 more · For: Coronary Artery Disease
- Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome (TICO Study)Pivotal-lookingStatus unknown
Yonsei UniversityAcademic, hospital or other
NCT02494895 · 3,056 participants (planned) · Start Aug 1, 2015 · Primary completion May 2023
Drug: Ticagrelor monotherapy; Ticagrelor with Aspirin DAPT(dual antiplatelet treatment) · For: Acute Coronary Syndrome
Sites: Seoul, South Korea
- Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast CancerPivotal-lookingCompleted
GBG Forschungs GmbHAcademic, hospital or other
NCT00567554 · 2,600 participants · Start Oct 2007 · Primary completion Aug 2011
Drug: epirubicin - cyclophosphamide / docetaxel; epirubicin - cyclophosphamide / docetaxel + bevacizumab and 4 more · For: Breast Cancer
Sites: Frankfurt am Main, Germany
- CYPRESS - CYPHER for Evaluating Sustained SafetyPivotal-lookingStatus unknown
Cordis US Corp.Industry
NCT00954707 · 2,509 participants · Start Aug 2009 · Primary completion Jan 2012
Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin; Placebo & Aspirin · For: Coronary Artery Disease
Sites: Cleveland, Ohio
- Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent ImplantationPivotal-lookingStatus unknown
Shanghai MicroPort Medical (Group) Co., Ltd.Industry
NCT03008083 · 2,446 participants (planned) · Start Jan 10, 2019 · Primary completion Dec 2020
Drug: 3 months DAPT; 12 months DAPT · For: Drug-Eluting Stents; Percutaneous Coronary Intervention
Sites: Shanghai, China
- Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet TherapyPivotal-lookingActive, not recruiting
iVascular S.L.U.Industry
NCT05952206 · 2,312 participants · Start Oct 13, 2023 · Primary completion Jan 13, 2027
Drug: 1-month DAPT; 12-month DAPT (Standard of care) · For: Coronary Artery Disease
Sites: Bonheiden, Belgium; Charleroi, Belgium; Genk, Belgium · 38 sites in all
- Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) TrialPivotal-lookingCompleted
Seoul National University HospitalAcademic, hospital or other
NCT02601157 · 2,173 participants · Start Jan 18, 2016 · Primary completion Aug 14, 2021
Drug: 3-months DAPT; 1-year DAPT · For: Stable Angina; Unstable Angina; Non-ST Segment Elevation Myocardial Infarction
Sites: Busan, South Korea; Cheonan, South Korea; Gwangju, South Korea · 12 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use2,076
- drug ineffective1,140
- product use in unapproved indication786
- pyrexia533
- diarrhoea529
- pneumonia500
- drug interaction450
- acute kidney injury444
- thrombotic microangiopathy386
- transplant rejection384
- cytomegalovirus infection355
- condition aggravated318
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 41 |
| 2005 | 53 |
| 2006 | 51 |
| 2007 | 232 |
| 2008 | 194 |
| 2009 | 294 |
| 2010 | 152 |
| 2011 | 253 |
| 2012 | 231 |
| 2013 | 204 |
| 2014 | 239 |
| 2015 | 315 |
| 2016 | 425 |
| 2017 | 598 |
| 2018 | 845 |
| 2019 | 990 |
| 2020 | 1,021 |
| 2021 | 1,054 |
| 2022 | 1,240 |
| 2023 | 1,139 |
| 2024 | 1,444 |
| 2025 | 1,502 |
| 2026 | 1,002 |
Recalls
1 FDA enforcement reports for this application.
Oct 13, 2022 · Class III · Terminated
Failed Stability Specifications
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Fyarro (Sirolimus Protein-Bound) · HCPCS J9331
2024 spending
$7.7M
Beneficiaries
34
378 claims
Per beneficiary
$225,713
2024 ASP limit $93.85 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $1,762,281 |
| 2023 | $8,104,505 |
| 2024 | $7,674,229 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Paclitaxel-coated versus sirolimus-coated balloon angioplasty for coronary artery disease: A systematic review and meta-analysis.
Shin D, Singh M, Shlofmitz E, et al. · Catheter Cardiovasc Interv 2024 · Comparative Study, Meta-Analysis
- Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review.
Freixo C, Ferreira V, Martins J, et al. · J Vasc Surg 2020 · Systematic Review
- Reduced exposure to calcineurin inhibitors in renal transplantation.
Ekberg H, Tedesco-Silva H, Demirbas A, et al. · N Engl J Med 2007 · Comparative Study, Multicenter Study
- Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial.
Maruani A, Tavernier E, Boccara O, et al. · JAMA Dermatol 2021 · Multicenter Study, Randomized Controlled Trial
- Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease.
Barco S, Engelberger RP, Held U, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Equivalence Trial
- Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial.
Redl A, Doberer K, Unterluggauer L, et al. · Lancet Rheumatol 2024 · Randomized Controlled Trial
Sponsor: Aadi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.